Novo Nordisk stock rises after Wegovy recommended by UK’s drug price regulator
Michael Siluk | UCG | Universal Images Group | Getty Images
Novo Nordisk It rose as much as 4 percent after Britain’s medicines price regulator recommended the use of its best-selling drug Wegovy to prevent heart attacks and strokes.
Wegovy is primarily a weight-loss treatment, but it is also approved to reduce the risk of major cardiovascular events in people living with overweight or obesity.
New advice from the National Institute for Health and Care Excellence (NICE), the UK’s medicines price regulator, will significantly expand access to Wegovy in the country’s National Health Service (NHS).
The regulator, which evaluates the cost-effectiveness of a drug, recommended semaglutide, the active ingredient in the diabetes treatment Wegovy and Ozempic, as an option for adults with a previous heart attack, stroke or serious circulation problem in the legs and a body mass index (BMI) of at least 27.
Novo’s Copenhagen-listed shares were last seen up 2% in morning trading, clawing back some of their earlier gains. Pan-European blue chip index Stoxx 600 It increased by 2.1%.
This is breaking news. Please refresh for updates.
